新冠神藥有效嗎? 中國實驗結果讓眾人一驚| Experimental Covid-19 treatment remdesivir flopped in China trial: FT

(圖/取自美聯社)

【看CP學英文】金融時報週四報導,中國持續研究的新冠肺炎解藥瑞德西韋經臨床試驗後,結果顯示此藥無法改善染疫者狀況,也無法去除病患血液中的病原體。

The Financial Times reported on Thursday that the Chinese trial of experimental coronavirus treatment remdesivir did not “improve patients’ condition” or “remove the pathogen’s presence” in their bloodstream.

根據世界衛生組織資料顯示,實驗記錄了237位病患,而其中接受此藥物的有158位。

According to draft documents published accidentally by the World Health Organization, the trial compiled data from 237 patients, 158 of whom received the drug.

然而服用此藥物的病人接續爆出有明顯副作用,導致18位病患終止藥物測試。

Significant side effects were reportedly seen in some patients, however, which meant that 18 were taken off the drug.

根據福斯新聞報導,一位吉利德科學公司的發言人表示世界衛生組織的報告中含有對於實驗「不當的描述」。

In a statement obtained by Fox News, a Gilead Sciences spokesperson said the WHO documents “included inappropriate characterizations” of the study.

發言人在聲明中寫道,「我們很遺憾世界衛生組織貿然貼出關於這項研究的資訊,目前該資訊已撤除。而且參與其中的研究人員當時並沒有授權同意發布研究結果。」

“We regret that the WHO prematurely posted information regarding the study, which has since been removed. The investigators in this study did not provide permission for publication of results,” the statement said.

福斯新聞也表示美國目前仍在等待瑞德西藥物被認可為新冠肺炎解藥。

In the U.S., Remdesivir is still awaiting regulatory approval as a coronavirus treatment, Fox News said.

瑞德西藥物在三月初時因新格蘭醫學雜誌於期刊中分析美國第一位新冠肺炎患者使用此藥物後症狀減緩的狀況,使其受到世界關注。

Remdesivir’s potential gained currency as a possible COVID-19 treatment in early March when the New England Journal of Medicine described the first case of the novel coronavirus in the U.S. and indicated that the drug mitigated the patient’s symptoms.

負責研究瑞德西韋的吉利德製藥團隊是由台灣女博士楊台瑩領軍,她畢業於台灣大學化學系,擁有臺大化學博士學位及南加州大學有機化學博士學位。

The Gilead research team for the development of remdesivir was led by a Taiwanese scientist, Taiyin Yang (楊台瑩) who received her bachelor’s degree from National Taiwan University (NTU) and her Ph.D. in organic chemistry from the University of Southern California (USC).

楊台瑩在2005年時受吉利德科學公司指派擔任藥品開發及製造部門執行副總裁,檢驗所有該公司出售的藥物和產品。

Yang was appointed executive vice president of pharmaceutical development and manufacturing by Gilead Sciences in 2005 and has since overseen all investigated compounds and marketed products in the company.